Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $918,000.

  • Janux Therapeutics' Other Accumulated Expenses fell 29.18% to $551,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $551,000, marking a year-over-year decrease of 29.18%. This contributed to the annual value of $918,000 for FY2024, which is 67.21% up from last year.
  • As of FY2024, Janux Therapeutics' Other Accumulated Expenses stood at $918,000, which was up 67.21% from $549,000 recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Other Accumulated Expenses registered a high of $918,000 during FY2024, and its lowest value of $399,000 during FY2020.
  • In the last 3 years, Janux Therapeutics' Other Accumulated Expenses had a median value of $623,000 in 2022 and averaged $696,667.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first dropped by 11.88% in 2023, then surged by 67.21% in 2024.
  • Janux Therapeutics' Other Accumulated Expenses (Yearly) stood at $399,000 in 2020, then climbed by 19.80% to $478,000 in 2021, then soared by 30.33% to $623,000 in 2022, then dropped by 11.88% to $549,000 in 2023, then soared by 67.21% to $918,000 in 2024.